2.09 USD
▼-0.03-2.34%
盘后 2.14 +0.22%
2026-08-03
市值
$133.10M
市盈率
—
EPS
-0.59
股息率
—
52 周区间
0.41 – 3.90
成交量
199.52K
Beta
—
目标价
8.04
52W 低 0.4152W 高 3.90
价格走势
公司简介
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company’s lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form...